Association of DRD3, COMT, and SLC6A4 Gene Polymorphisms with Type 2 Diabetes in Southern Chinese: A Hospital-Based Case-Control Study.

Abstract:

AIM:The aim of this study was to assess the associations of six single nucleotide polymorphisms (SNPs) of three genes (DRD3, COMT, and SCL6A4) with type 2 diabetes mellitus (T2DM) in Southern Chinese. SUBJECTS AND METHODS:Five hundred ninety-five cases with T2DM and 725 healthy controls of Han origin were recruited from six hospitals in Guangdong Province, Southern China. Fasting serum concentrations of markers of interest (total cholesterol, triglyceride, plasma glucose, etc.) were measured in hospitals. SNP genotyping was performed using a custom-by-design 2-×48-Plex SNPscan™ kit (Genesky Biotechnologies Inc., Shanghai, China). Single-point SNP analysis, haplotype analysis, and SNP-SNP interactions were carried out. RESULTS:SNP rs4646312 in COMT achieved statistical significance in both allelic association and genotypic association and even after adjusting covariates (odds ratio [OR]=1.26; 95% confidence interval [CI], 1.04-1.53; P=0.021). Two haplotypes consisting of rs4646312 and rs4680 were also significantly associated with T2DM, of which C-G was a protective haplotype for T2DM (OR=0.83; 95% CI, 0.70-0.98; P=0.029), whereas T-A was a risk one (OR=1.23, 95% CI, 1.03-1.46; P=0.022). Interaction analysis identified a significant epistatic effect between rs4680 in COMT and rs2066713 in SCL6A4 after adjusting for covariates (OR=3.59, 95% CI, 1.72-7.48; P=0.001 for dominant-dominant model). However, only the interaction between rs4680 and rs2066713 was significant, and haplotype T-A showed a marginally increased risk after Bonferroni correction. CONCLUSIONS:The genetic polymorphisms in COMT and SCL6A4 confer significant effects in joint actions to T2DM in Southern Chinese.

journal_name

Diabetes Technol Ther

authors

Xiu L,Lin M,Liu W,Kong D,Liu Z,Zhang Y,Ouyang P,Liang Y,Zhong S,Chen C,Jin X,Fan X,Qin J,Zhao X,Rao S,Ding Y

doi

10.1089/dia.2014.0344

subject

Has Abstract

pub_date

2015-08-01 00:00:00

pages

580-6

issue

8

eissn

1520-9156

issn

1557-8593

journal_volume

17

pub_type

杂志文章
  • Active assistance technology reduces glycosylated hemoglobin and weight in individuals with type 2 diabetes: results of a theory-based randomized trial.

    abstract:BACKGROUND:Type 2 diabetes is an individual health challenge requiring ongoing self-management. Remote patient reporting of relevant health parameters and linked automated feedback via mobile telephone have potential to strengthen self-management and improve outcomes. This research involved development and evaluation o...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1089/dia.2013.0056

    authors: Orsama AL,Lähteenmäki J,Harno K,Kulju M,Wintergerst E,Schachner H,Stenger P,Leppänen J,Kaijanranta H,Salaspuro V,Fisher WA

    更新日期:2013-08-01 00:00:00

  • The emergence of biosimilar insulin preparations--a cause for concern?

    abstract::Several biopharmaceuticals, including insulin and insulin analogs, are, or shortly will be, off-patent, thereby providing an opportunity for companies to attempt to manufacture "copies" commonly referred to as biosimilars and also known as follow-on biologics. Reassurance that such copy biologics are equally safe and ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/dia.2012.0105

    authors: Owens DR,Landgraf W,Schmidt A,Bretzel RG,Kuhlmann MK

    更新日期:2012-11-01 00:00:00

  • Accuracy of glycemic measurements in the critically ill.

    abstract:BACKGROUND:Recent evidence emphasizes the importance of maintaining normoglycemia in critically ill patients to reduce morbidity and mortality. Different analytical methods of varying accuracy exist for obtaining and measuring blood glucose in critically ill patients. The purpose of this study was to determine if there...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2008.0263

    authors: Slater-MacLean L,Cembrowski G,Chin D,Shalapay C,Binette T,Hegadoren K,Newburn-Cook C

    更新日期:2008-06-01 00:00:00

  • Role of chronic and acute hyperglycemia in the development of diabetes complications.

    abstract::Chronic hyperglycemia, as assessed by hemoglobin A1c (HbA1c) levels, has been associated with the development of microvascular and macrovascular complications of diabetes. Several studies have shown that acute hyperglycemia can add to the effect of chronic hyperglycemia in inducing tissue damage. Acute hyperglycemia c...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/dia.2010.0146

    authors: Marcovecchio ML,Lucantoni M,Chiarelli F

    更新日期:2011-03-01 00:00:00

  • Clinical trial of a noninvasive contact lens glucose sensor.

    abstract:OBJECTIVE:The purpose of the present study was to determine the effectiveness of a fluorescent contact lens glucose sensor in monitoring glucose in patients with diabetes. METHODS:Under an institutional review board-approved protocol, five fasting patients with type II diabetes were given a challenge consisting of 75 ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1089/dia.2004.6.782

    authors: March WF,Mueller A,Herbrechtsmeier P

    更新日期:2004-12-01 00:00:00

  • Combining basal insulin analogs with glucagon-like peptide-1 mimetics.

    abstract::Basal insulin analogs are recognized as an effective method of achieving and maintaining glycemic control for patients with type 2 diabetes. However, the progressive nature of the disease means that some individuals may require additional ways to maintain their glycemic goals. Intensification in these circumstances ha...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/dia.2010.0250

    authors: Perfetti R

    更新日期:2011-09-01 00:00:00

  • Clinical predictors of glycosylated hemoglobin response to thiazolidinedione therapy.

    abstract:BACKGROUND:The aim of this investigation was to assess clinical predictors of the glycosylated hemoglobin (HbA1C) response after the addition of a thiazolidinedione (TZD) to a biguanide, a sulfonylurea, or both in subjects with type 2 diabetes. METHODS:Chart review (n = 68 physicians) was used to identify consecutive ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2007.0248

    authors: Izumi R,Hurt J,Maki KC,Bell M,Zavras AI,McCamish M

    更新日期:2007-12-01 00:00:00

  • Can continuous subcutaneous insulin infusion improve health-related quality of life in patients with Shwachman-Bodian-Diamond syndrome and diabetes?

    abstract::We report the first case of the use of continuous subcutaneous insulin infusion (CSII) in a patient with Shwachman-Bodian-Diamond syndrome (SBDS) and diabetes. An Italian boy received diagnosis of SBDS at the age of 7 months (SBDS gene mutation: c.183-184TA → CT and c.258 + 2 T → C in compound heterozygous). The patie...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2014.0184

    authors: Terlizzi V,Zito E,Mozzillo E,Raia V,Franzese A

    更新日期:2015-01-01 00:00:00

  • Patient perceptions of using the OmniPod system compared with conventional insulin pumps in young adults with type 1 diabetes.

    abstract:AIMS:This study evaluated treatment satisfaction, comfort, and function using the wireless OmniPod™ Insulin Management System (Insulet Corp., Bedford, MA) compared with conventional (infusion set) insulin pumps in young adults with type 1 diabetes. RESEARCH DESIGN AND METHODS:Twenty-nine patients (age, 24.0 ± 5.1 year...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1089/dia.2011.0228

    authors: Lebenthal Y,Lazar L,Benzaquen H,Shalitin S,Phillip M

    更新日期:2012-05-01 00:00:00

  • Effects of sleep apnea severity on glycemic control in patients with type 2 diabetes prior to continuous positive airway pressure treatment.

    abstract:BACKGROUND:Obstructive sleep apnea (OSA), a highly prevalent condition, is independently associated with increased risks of developing type 2 diabetes mellitus (T2D) and metabolic syndrome. It is unclear, however, if the severity of OSA has any impact on glycemic control among patients with T2D. We therefore aimed to d...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2011.0005

    authors: Pillai A,Warren G,Gunathilake W,Idris I

    更新日期:2011-09-01 00:00:00

  • A highly sensitive immunoassay resistant to autoantibody interference for detection of the diabetes-associated autoantigen glutamic acid decarboxylase 65 in blood and other biological samples.

    abstract:BACKGROUND:Glutamic acid decarboxylase-65 (GAD65) is a major autoantigen in autoimmune diabetes and is discharged from injured islet beta cells. GAD65 may also be released by transplanted islets undergoing immunological rejection. To test hypotheses regarding the utility of GAD65 as a biomarker for transplant rejection...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2006.8.207

    authors: Waldrop MA,Suckow AT,Hall TR,Hampe CS,Marcovina SM,Chessler SD

    更新日期:2006-04-01 00:00:00

  • Psychosocial correlates of continuous glucose monitoring use in youth and adults with type 1 diabetes and parents of youth.

    abstract:BACKGROUND:Continuous glucose monitoring (CGM) has been shown to improve glycemic control and reduce hypoglycemia with consistent use. Youth, however, are unlikely to use CGM consistently. We compared psychological characteristics of youth with type 1 diabetes, their parents, and adults with type 1 diabetes randomized ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1089/dia.2011.0201

    authors: Markowitz JT,Pratt K,Aggarwal J,Volkening LK,Laffel LM

    更新日期:2012-06-01 00:00:00

  • Real-World Hypoglycemia Avoidance with a Continuous Glucose Monitoring System's Predictive Low Glucose Alert.

    abstract:BACKGROUND:Programmable and fixed auditory and/or vibratory threshold alerts are essential features of real-time continuous glucose monitoring (rtCGM) systems that provide users time to intervene before the onset of clinical hypoglycemia or hyperglycemia. A sixth-generation rtCGM system from Dexcom, Inc. (G6) includes ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2018.0359

    authors: Puhr S,Derdzinski M,Welsh JB,Parker AS,Walker T,Price DA

    更新日期:2019-04-01 00:00:00

  • Integrating Continuous Glucose Monitor Data Directly into the Electronic Health Record: Proof of Concept.

    abstract:: Background: Continuous glucose monitoring (CGM) systems are widely and increasingly used in diabetes self-management and in the context of clinic visits. However, access to CGM data during visits can be challenging. Clinic inefficiencies can restrict the time available for...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2019.0377

    authors: Espinoza J,Shah P,Raymond J

    更新日期:2020-08-01 00:00:00

  • NerveCheck for the Detection of Sensory Loss and Neuropathic Pain in Diabetes.

    abstract:BACKGROUND:Accurate and economic detection of nerve damage in diabetes is key to more widespread diagnosis of patients with diabetic peripheral neuropathy (DPN) and painful diabetic neuropathy. This study examined the diagnostic performance of NerveCheck, an inexpensive ($500) quantitative sensory testing (QST) device....

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2016.0279

    authors: Ponirakis G,Odriozola MN,Odriozola S,Petropoulos IN,Azmi S,Ferdousi M,Fadavi H,Alam U,Marshall A,Jeziorska M,Miro A,Kheyami A,Tavakoli M,Al-Ahmar A,Odriozola MB,Odriozola A,Malik RA

    更新日期:2016-12-01 00:00:00

  • Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 1 Diabetes Also Using Insulin Glargine-SORELLA 1 Study.

    abstract:BACKGROUND:SAR342434 is a biosimilar follow-on of insulin lispro-Humalog®. This study aimed to show similar efficacy, safety, and immunogenicity of SAR342434 (SAR-Lis) versus insulin lispro-Humalog (Ly-Lis) in adult patients with type 1 diabetes (T1DM) treated with multiple daily injections while using basal insulin gl...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1089/dia.2017.0117

    authors: Garg SK,Wernicke-Panten K,Rojeski M,Pierre S,Kirchhein Y,Jedynasty K

    更新日期:2017-09-01 00:00:00

  • Continuous Subcutaneous Insulin Infusion in Neonates and Infants Below 1 Year: Analysis of Initial Bolus and Basal Rate Based on the Experiences from the German Working Group for Pediatric Pump Treatment.

    abstract:BACKGROUND:Diabetes mellitus is rare in young infants and neonates. Continuous subcutaneous insulin infusion (CSII) is used most frequently for insulin treatment in this age group. However, the individual doctor's experience is scarce because of the low prevalence of diabetes in this age. For this study patients treate...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1089/dia.2015.0030

    authors: Kapellen TM,Heidtmann B,Lilienthal E,Rami-Merhar B,Engler-Schmidt C,Holl RW

    更新日期:2015-12-01 00:00:00

  • Performance evaluation of the GlucoDr plus glucometer.

    abstract:BACKGROUND:Because strict glucose control is important for reducing the complications of diabetes, the self-monitoring of blood glucose is one of the fundamental treatment modalities. Many glucometers have been developed. In the present study, we evaluated a new glucometer: GlucoDr Plus (Allmedicus, Anyang, Gyeonggi-do...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2009.0134

    authors: Ko DH,Lim S,Song SH,Choi SH,Park YJ,Park KU,Jang HC,Song J

    更新日期:2010-04-01 00:00:00

  • The influence of environmental temperature on the response of the skin to local pressure: the impact of aging and diabetes.

    abstract:BACKGROUND:To protect against ischemia, pressure-induced vasodilation (PIV) causes an increase in skin blood flow. Endothelial dysfunction, which is commonly found in older patients and those with diabetes, and global temperatures can affect the resting blood flow in skin, which may reduce the blood flow during and aft...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2009.0097

    authors: McLellan K,Petrofsky JS,Zimmerman G,Lohman E,Prowse M,Schwab E,Lee S

    更新日期:2009-12-01 00:00:00

  • Role of continuous subcutaneous insulin infusion in patients with recalcitrant diabetes in South India.

    abstract:BACKGROUND:We aimed to assess the effect of continuous subcutaneous insulin infusion (CSII) therapy in patients with "recalcitrant diabetes" whose glycemia had not been controlled adequately with multiple daily injections of insulin or insulin plus oral hypoglycemic agents. PATIENTS AND METHODS:We retrospectively anal...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2009.0066

    authors: Sudhakaran C,Anjana RM,Rao K,Unnikrishnan R 1st,Suresh T,Mohan V

    更新日期:2009-11-01 00:00:00

  • Validation of the SoloSTAR insulin pen.

    abstract:BACKGROUND:This study was designed to validate the use of SoloSTAR (sanofi-aventis Deutschland GmbH, Frankfurt, Germany), a new disposable pen developed for use with insulin glargine by patients with type 1 or type 2 diabetes. METHODS:This single-center, open-label, single-arm, sequential trial enrolled subjects with ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1089/dia.2008.0079

    authors: Schwartz S,Vlajnic A

    更新日期:2008-10-01 00:00:00

  • The Impact of Short-Term Professional Continuous Glucose Monitoring on Glycemic Control Via Lifestyle Improvement.

    abstract:BACKGROUND:The efficacy of short-term professional continuous glucose monitoring (CGM) for glycemic control in patients with diabetes remains unclear. METHODS:We performed a 3-month study to evaluate the benefits of CGM in 64 patients. RESULTS:The overall glycemic control of patients who underwent CGM improved signif...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2018.0164

    authors: Shibusawa R,Yamada E,Okada S,Nakajima Y,Bastie CC,Yamada M

    更新日期:2018-09-01 00:00:00

  • Home blood glucose prediction: validation, safety, and efficacy testing in clinical diabetes.

    abstract:BACKGROUND:Patients with diabetes do daily self-monitoring of blood glucose (SMBG). For such patients, we devised an engine that predicts not only the expected blood glucose level at the next meal but also the pending risks of hypoglycemia. The purpose of this study was to validate the predictions and provide evidence ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2005.7.487

    authors: Albisser AM,Sakkal S,Wright C

    更新日期:2005-06-01 00:00:00

  • Behavioral Patterns and Associations with Glucose Control During 12-Week Randomized Free-Living Clinical Trial of Day and Night Hybrid Closed-Loop Insulin Delivery in Adults with Type 1 Diabetes.

    abstract:OBJECTIVES:We evaluated patterns of meal intake, insulin bolus delivery, and fingerstick glucose measurements during hybrid closed-loop and sensor-augmented pump (SAP) therapy, including associations with glucose control. METHODS:Data were retrospectively analyzed from pump-treated adults with type 1 diabetes who unde...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1089/dia.2016.0307

    authors: Emami A,Willinska ME,Thabit H,Leelarathna L,Hartnell S,Dellweg S,Benesch C,Mader JK,Holzer M,Kojzar H,Pieber TR,Arnolds S,Evans ML,Hovorka R

    更新日期:2017-07-01 00:00:00

  • Evaluating rate of change as an index of glycemic variability, using continuous glucose monitoring data.

    abstract:BACKGROUND:There is no consensus as to the best method to assess glycemic variability from continuous glucose monitoring (CGM) data. Rate of change has been suggested as a preferred method of assessing glycemic variability, but this assertion has not been validated. METHODS:Forty-eight hours of CGM data were analyzed ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1089/dia.2010.0215

    authors: Whitelaw BC,Choudhary P,Hopkins D

    更新日期:2011-06-01 00:00:00

  • Continuous glucose monitoring pilot in low-income type 1 diabetes patients.

    abstract:BACKGROUND:Continuous glucose monitoring (CGM) has been shown to be a valuable tool to improve glycemic control in patients with diabetes. The objective of this pilot study was to develop and implement CGM in an existing diabetes clinic for low-income patients on multiple daily injections. SUBJECTS AND METHODS:This wa...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1089/dia.2013.0072

    authors: Sequeira PA,Montoya L,Ruelas V,Xing D,Chen V,Beck R,Peters AL

    更新日期:2013-10-01 00:00:00

  • Regulatory aspects of invasive glucose measurements.

    abstract::On May 26, 1976, the Food and Drug Administration (FDA) began implementing the Medical Device Amendments to the Federal Food Drug and Cosmetic Act. These amendments give FDA specific authority to regulate "medical devices." Additional authority was provided in the Safe Medical Devices Act of 1990. The pathways to get ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/152091502321118784

    authors: Gutman S,Bernhardt P,Pinkos A,Moxey-Mims M,Knott T,Cooper J

    更新日期:2002-01-01 00:00:00

  • Frequency of the dawn phenomenon in type 2 diabetes: implications for diabetes therapy.

    abstract::This study was designed to assess the frequency of the dawn phenomenon in patients with type 2 diabetes. A secondary aim was to examine the influence of varying treatment regimens on the frequency of the dawn phenomenon. The dawn phenomenon was defined as a rise in plasma glucose levels of > or = 0.5 mmol/L (10 mg/dL)...

    journal_title:Diabetes technology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1089/152091502320798213

    authors: Carroll MF,Hardy KJ,Burge MR,Schade DS

    更新日期:2002-01-01 00:00:00

  • Comparison of Metabolic Outcomes in Children Diagnosed with Type 1 Diabetes Through Research Screening (Diabetes Autoimmunity Study in the Young [DAISY]) Versus in the Community.

    abstract:BACKGROUND:Children with positive islet autoantibodies monitored prospectively avoid metabolic decompensation at type 1 diabetes (T1D) diagnosis. However, the effects of early diagnosis and treatment on preservation of insulin secretion and long-term metabolic control are unknown. We compared characteristics of childre...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2015.0029

    authors: Chan CL,Taki I,Dong F,Hoffman M,Norris JM,Klingensmith G,Rewers MJ,Steck AK

    更新日期:2015-09-01 00:00:00

  • Minimally invasive insulin delivery in subjects with type 1 diabetes using hollow microneedles.

    abstract:BACKGROUND:Microneedles have previously been used to deliver insulin to animal models, but not in human subjects. This study tested the hypothesis that hollow microneedles can deliver insulin to modulate blood glucose levels in subjects with type 1 diabetes in a minimally invasive manner. METHODS:This study was carrie...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2008.0103

    authors: Gupta J,Felner EI,Prausnitz MR

    更新日期:2009-06-01 00:00:00